All Posts

What’s New in Femtech This Week? (June 10, 2021)

Every Thursday we send out a curated newsletter on “all things femtech and women’s health innovation”. This is the latest edition. If you’re interested in subscribing, you can do so at the bottom of this page. You’ve found some of our exclusive Inner Circle Content. This article is only available for our Inner Circle Members. To read on: Sign in to your…

Agendia’s MammaPrint Spots Ultra-Low Breast Cancer Recurrence Risks Helping Identify Women Who Could Skip Chemo

Breast cancer test maker Agendia has released new data suggesting its MammaPrint genomic diagnostic spots breast cancer patients with ultra-low risk of recurrence, who could skip chemo and are likely to keep cancer at bay for at least 20 years. This information, culled from an analysis of 70 different genes, could help oncologists tailor treatment plans for certain early-stage breast cancer cases,…

Report: CBD and Women’s Health (Rae Wellness & Radicle Science)

Radicle Science and Rae Wellness have recently announced a new CBD study focused exclusively on CBD and Women’s Health. The Rae Wellness study on CBD and Women’s Health is one of the first and largest randomized, controlled human studies to evaluate the effects of commercially available non-prescription CBD products. To our knowledge, it represents the first CBD study to focus exclusively on women’s health…

Gynesonics’ Sonata System Is Now Covered by Cigna for the Treatment of Uterine Fibroids

Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that Cigna has released a national coverage policy for treatment of uterine fibroids with the Sonata System.  The Sonata System uses radiofrequency energy to ablate fibroids under real time sonography guidance from within the uterine cavity, utilizing the first and only intrauterine ultrasound…

OvuSense Manufacturer Fertility Focus Announces the Launch of OvuFirst, a New Skin-Worn Sensor for Ovulation Tracking

Fertility Focus, the manufacturers of the OvuCore and OvuSense Pro family of fertility monitoring solutions, today announces the launch of OvuFirst, a unique patented sensor designed to measure skin temperature, providing women with an understanding of when to try and conceive naturally, and enabling them to determine what issues they may have trying to conceive. OvuFirst is targeted at women who wish…

Auransa and POLARISqb Enter Research Collaboration to Find Treatments for Neglected Women’s Diseases Like Endometriosis and PCOS

Auransa, an artificial intelligence (AI) company developing precision medicines in areas of unmet medical needs, and Polaris Quantum Biotech (POLARISqb), a quantum drug design company, announced a research collaboration addressing therapeutics for neglected diseases disproportionately affecting women. The partnership seeks to discover treatments that may tackle many such diseases, and their complementary expertise promises to seek solutions that elude medical research.  Auransa…

Cigna Now Covers Hologic’s Acessa Procedure for Uterine Fibroids

Women’s health company Hologic has announced a new parntership with Cigna, one of the largest global health insurance service companies. Cigna has updated its medical policy to cover Hologic’s Acessa Laparoscopic Radiofrequency Ablation (Lap-RFA) procedure (CPT code 58674) as medically necessary. This new coverage further validates laparoscopic radiofrequency ablation (Lap-RFA) as a standard of care for uterine fibroids. The Acessa procedure can…

#VulvaTalk: Callaly Launches “We Need to Talk about Vulvas Campaign” to Dispel the Myth of the Perfect Vulva

Period-care brand Callaly has launched “We Need to Talk About Vulvas”, a new campaign to encourage #VulvaTalk and debunk “the myth of the perfect vulva”, centering diverse, real life experiences of people with vulvas and providing new educational material for parents, educators and people with vulvas. The campaign launches with research showing almost a third (29%) of people aged 16 to 35…